Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Galectin Therapeutics Inc expected to post a loss of 5 cents a share - Earnings Preview

By Reuters News

  • Galectin Therapeutics Inc GALT.O is expected to show no change in quarterly revenue when it reports results on November 12 (estimated) for the period ending September 30 2026


  • ​LSEG's mean analyst estimate for Galectin Therapeutics Inc is for a loss of 5 cents per share.

  • The one available analyst rating on the shares is "buy".

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Galectin Therapeutics Inc is $11.00, about 217.9% above its last closing price of $3.46

This summary was machine generated November 10 at 13:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.